NCT07916324
Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
Participants assigned to this arm will receive intradermal hyaluronidase injections in the left hand, while the right hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.
Participants assigned to this arm will receive intradermal hyaluronidase injections in the right hand, while the left hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.
Drugs: hyaluronidase
Sites
1 site in 1 country
- Stanford UniversityStanford, California, United States